Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bicalutamide 50 mg Clear all
Active, not recruiting Not applicable Interventional Results available

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Dutasteride, Finasteride, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

NCT05100472
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 9, 2026, 11:46 PM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance

NCT02146937
View directory record Official record
Conditions
Detectable Prostate Nodules
Interventions
Bicalutamide plus Finasteride- Combination therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

NCT01809691
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Bicalutamide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
560
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 9, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

NCT07455903
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 9, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

NCT00814788
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Everolimus
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 9, 2026, 11:46 PM EDT
Recruiting Phase 1 Interventional

Bicalutamide Therapy in Young Women With NAFLD and PCOS

NCT05979389
View directory record Official record
Conditions
NAFLD, PCOS
Interventions
Bicalutamide 50 mg, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 9, 2026, 11:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

NCT01020305
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer, Hormone-refractory Prostate Cancer, Metastatic Disease
Interventions
Temsirolimus, Casodex (bicalutamide)
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 9, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 9, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 9, 2026, 11:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 9, 2026, 11:46 PM EDT
Terminated Phase 3 Interventional Results available

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

NCT00003645
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Leuprolide Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT00666666
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Interventions
AT-101, Bicalutamide, LHRH agent
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 9, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

NCT00521781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abraxane, Leuprolide, Bicalutamide
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 9, 2026, 11:46 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

NCT03650894
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
Interventions
Nivolumab, Ipilimumab, Bicalutamide
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00026377
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chicago, Illinois • LaGrange, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 9, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

NCT00630344
View directory record Official record
Conditions
Prostate Cancer
Interventions
RAD001, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 9, 2026, 11:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

NCT00924807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate, Bicalutamide, Sorafenib
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 9, 2026, 11:46 PM EDT